Eloxx Pharmaceuticals has appointed Geno Germano, a biopharmaceutical veteran with over 35 years of leadership experience, to its Board of Directors. Germano's expertise in drug development and commercialization, including his past roles at Pfizer and other biotech firms, is expected to support Eloxx's advancement of exaluren, a treatment for rare kidney diseases. This move aims to strengthen the company's clinical programs targeting genetic causes of these diseases. Germano expressed enthusiasm about contributing to the company's growth and patient impact.
Eloxx Pharmaceuticals' board appointment news comes with this Pluang market snapshot for health-sector stocks as of Oct 20, 2026 03:02 WIB: Out of 150 priced stocks, 87 rose and 62 fell. Notable movers include ImmunityBio Inc. (IBRX) at USD 8.46 with a 1-day change of -7.84%, Dyne Therapeutics Inc. (DYN) at USD 15.31 up 7.44%, and Tango Therapeutics Inc. (TNGX) at USD 23.60 up 7.08%.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
